BRUSSELS (Reuters) - Belgian pharma group UCB said on Monday that U.S. health authorities had approved epilepsy drug Keppra XR and that it would go on sale just before its mother drug loses patent ...

UCB today announced findings from new studies of the once-daily antiepileptic drug (AED) Keppra XR™ (levetiracetam) extended-release tablets comparing tolerability vs. levetiracetam immediate release ...

-- Online survey shows people living with epilepsy often miss a dose of their antiepileptic drug -- UCB continues to build on the company's commitment to patients living with epilepsy through the ...

KEPPRA XR (Levetiracetam) 500mg, 750mg ext-rel tablets by UCB Keppra XR (levetiracetam) extended-release tablets have been made available by UCB in a 750mg dosage strength. Keppra XR (levetiracetam) ...

MORRISTOWN, N.J. — Actavis has launched its version of an epilepsy drug made by UCB. The generic drug maker said it received approval from the Food and Drug Administration for levetiracetam ...

MORRISTOWN, N.J., Sept. 15, 2011 /PRNewswire/ -- Actavis, an international generic pharmaceutical company, today announced that it has received FDA approval of Levetiracetam Extended-Release Tablets, ...

September 15, 2008 — The US Food and Drug Administration (FDA) has approved an extended-release formulation of levetiracetam (Keppra XR, UCB) as a new add-on treatment for partial-onset seizures. The ...

Keppra XR (levetiracetam extended-release tablets, from UCB) has been FDA approved for use as an adjunct in partial-onset seizures in patients ≥16yrs of age. Keppra is already available in ...

ATLANTA UCB has released a new formulation of an epilepsy drug, the Belgian drug maker announced Friday. The company released a 750 mg formulation of the drug Keppra XR (levetiracetam) ...

January 19, 2007 — The European Commission has approved levetiracetam for the adjunctive treatment of primary generalized tonic-clonic seizures in patients aged 12 years and older with refractory ...

Belgium’s UCB and Teva Pharmaceutical Industries have entered into a pact which will see the two companies jointly commercialise the Israeli-headquartered firm's respiratory medicines in the USA.